CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
NCT ID: NCT04097444
Last Updated: 2019-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
112 participants
INTERVENTIONAL
2019-10-11
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is composed two steps because of confirming of recommended dose (RD) for CAPOXIRI+BEV regimen.
1. Dose finding step (Step1): CAPOXIRI+BEV doses findings were planned by 3+3 cohort design, register up to maximum of 12 cases.
2. Randomised step (Step2): After confirmation of RD regarding CAPOXIRI+BEV, we will move to Step2 to compare the efficacy and safety between FOLFOXIRI+BEV and CAPOXIRI+BEV, register up to 65 cases.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Step 1 (CAPOXIRI+ BEV)
Induction therapy is followed by the maintenance therapy.
\[Induction treatment: CAPOXIRI+BEV\] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) oxaliplatin (OX): 100/130 mg/sq.m (d.i.v.) irinotecan (IRI):150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. OX/IRI dose is applied according to the progress of Step 1.
\[Maintenance treatment: 5-fluorouracil (FU)/Levofolinate calcium (LV)+BEV or CAP+BEV\] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).
5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks.
Bevacizumab
Given IV
Irinotecan hydrochloride
Given IV
Oxaliplatin
Given IV
Capecitabine
Given PO
Step 2 Arm A (FOLFOXIRI+ BEV)
Induction therapy is followed by the maintenance therapy.
\[Induction treatment: FOLFOXIRI+BEV\] Administered for 8 cycles (a maximum of 12 cycles). BEV: 5mg/kg (d.i.v.) OX: 85 mg/sq.m (d.i.v.) IRI:165mg/sq.m (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
\[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV\] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).
5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. Day1-15) Administered every 3 weeks.
Bevacizumab
Given IV
5-fluorouracil
Given IV
Leucovorin calcium
Given IV
Irinotecan hydrochloride
Given IV
Oxaliplatin
Given IV
Step 2 Arm B (CAPOXIRI+ BEV)
Induction therapy is followed by the maintenance therapy.
\[Induction treatment: CAPOXIRI+BEV\] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) OX: 100/130 mg/sq.m (d.i.v.) IRI:150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. Regarding to OX/IRI dose, RD will be confirmed at Step 1.
\[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV\] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).
5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks.
Bevacizumab
Given IV
Irinotecan hydrochloride
Given IV
Oxaliplatin
Given IV
Capecitabine
Given PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Given IV
5-fluorouracil
Given IV
Leucovorin calcium
Given IV
Irinotecan hydrochloride
Given IV
Oxaliplatin
Given IV
Capecitabine
Given PO
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically confirmed colon or rectal adenocarcinoma
\*Excluding appendix cancer and anal canal cancer
3. Clinically unresectable
4. ≥20 years of age at enrollment
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1 (≥71 years of age: PS score of 0)
6. Measurable lesion according to RECIST ver. 1.1 criteria on contrast-enhanced chest, abdominal, or pelvic (trunk) CT (required within 28 days of enrollment)
7. No previous chemotherapy for colon or rectal cancer
\*Patients with confirmed relapse ≥24 weeks after completion of post-operative adjuvant chemotherapy can be enrolled
8. Ras/Braf mutation analysis at enrollment identifies Ras/Braf status as either the wild type or mutant type.
9. Vital organ functions meet the following criteria within 14 days before enrollment.
If multiple test results are available in that period, the results closest to enrollment will be used. No blood transfusions or hematopoietic factor administration will be permitted within 2 weeks before the date on which measurements are taken.
i. Neutrophil count: ≥1,500 /cu.mm
ii. Platelet count: ≥10.0 × 104/cu.mm
iii. Hemoglobin concentration: ≥9.0 g/dL
iv. Total bilirubin: ≤1.5 times upper limit of normal (ULN)
v. Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP): ≤2.5 times ULN (≤5 times ULN for metastases to liver)
vi. Serum creatinine: ≤1.5 times ULN, or creatinine clearance: ≥30 mL/min
vii. Urine protein: ≤2+ (if ≥3+, urine protein/creatinine ratio: \<2.0)
10. UGT1A1 polymorphism is wild type or single heterozygous type -
Exclusion Criteria
2. Untreated brain metastases, spinal cord compression, or primary brain tumor
3. History of central nervous system (CNS) disease (excluding asymptomatic lacunar infarction)
4. Continuous systemic corticosteroid treatment is required
5. Oral or parenteral (such as low molecular weight heparin) anticoagulant dose is not consistently (≥14 days) controlled. (Oral anticoagulants: conditions at high risk for bleeding, such as prothrombin time (PT)-international normalized ratio (INR) ≥3, clinically significant active bleeding (within 14 days of enrollment))
6. Evidence of cardiovascular disease, cerebrovascular disorder (within 24 weeks), myocardial infarction (within 24 weeks), unstable angina pectoris, New York Heart Association (NYHA) classification ≥Grade II congestive heart failure, serious arrhythmias requiring drug therapy
7. Previous treatment with an investigational drug within 28 days prior to enrollment, or participation in a study of an unapproved drug
8. Any of the following comorbidities
i. Uncontrolled hypertension
ii. Uncontrolled diabetes mellitus
iii. Uncontrolled diarrhea
iv. Peripheral sensory neuropathy (≥Grade 1)
v. Active peptic ulcer
vi. Unhealed wound (except for suturing associated with implanted port placement)
vii. Other clinically significant disease (such as interstitial pneumonia or renal impairment)
9. Major surgical procedure within 28 days prior to study treatment initiation (such as open chest, laparoscopy, thoracoscopic surgery, laparoscopic surgery), unless only colostomy is performed; open biopsy or suturing for major trauma within 14 days of study treatment initiation; or planned major surgical procedure during the study (open chest, laparoscopy) ("major surgical procedures" does not include central venous (CV) port insertion)
10. Physical defects of the upper gastrointestinal tract; malabsorption syndrome or difficulty taking oral medication
11. Pregnant, breastfeeding, positive pregnancy test (women who have menstruated in the last year will be tested), or women who are unwilling to use contraception; men who are unwilling to use contraception during the study
12. Active hepatitis B or C, or evidence of HIV infection
13. Previous chemotherapy for other malignancies (excluding hormone therapy for breast cancer)
14. Other active malignancies (synchronous malignancies, and asynchronous malignancies separated by a 5-year disease-free interval) (excluding malignancies that are expected to be completely cured, such as intramucosal carcinoma and carcinoma in situ)
15. Uncontrolled venous thromboembolism (unless clinically stable, asymptomatic, or appropriately treated with an anticoagulant)
16. Arterial thrombosis or arterial thromboembolism such as myocardial infarction, transient ischemic attack, or cerebrovascular attack in the last year prior to enrollment
17. Complications such as intestinal paralysis, intestinal obstruction, or gastrointestinal perforation, current or within 1 year prior to enrollment
18. Pleural effusion, ascites, or pericardial effusion requiring drainage
19. History of hypersensitivity to fluorouracil, levofolinate, oxaliplatin, irinotecan, bevacizumab and their excipients or Chinese hamster ovary cell proteins
20. History of adverse reactions to fluoropyrimidine drugs indicative of dihydropyrimidine dehydrogenase (DPD) deficiency
21. Systemic treatment required for, or evidence of, infections
22. Endoluminal stenting
23. Otherwise unsuitable for the study in the opinion of investigators -
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chugai Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Takeshi Kato, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Surgery, National Hospital Organization Osaka National Hospital.
Akihito Tsuji, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Medical Oncology, Kagawa University Hospital.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ac Medical Inc.
Chuo Ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tsunehiko Tateuchi
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Bando H, Kotani D, Satake H, Hamaguchi T, Shiozawa M, Kotaka M, Masuishi T, Yasui H, Kagawa Y, Komatsu Y, Oki E, Yamamoto Y, Kawakami H, Misumi T, Taniguchi H, Yamazaki K, Muro K, Yoshino T, Kato T, Tsuji A. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC. Med. 2024 Sep 13;5(9):1164-1177.e3. doi: 10.1016/j.medj.2024.05.012. Epub 2024 Jun 19.
Kotani D, Yoshino T, Kotaka M, Kawazoe A, Masuishi T, Taniguchi H, Yamazaki K, Yamanaka T, Oki E, Muro K, Komatsu Y, Bando H, Satake H, Kato T, Tsuji A. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study. Invest New Drugs. 2021 Dec;39(6):1649-1655. doi: 10.1007/s10637-021-01125-2. Epub 2021 May 21.
Miyo M, Kato T, Yoshino T, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer. 2020 Jul 23;20(1):687. doi: 10.1186/s12885-020-07186-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QUATTRO-II
Identifier Type: -
Identifier Source: org_study_id